SATELLOS BIOSCIENCE
Satellos Bioscience is a regenerative medicine company formed in 2018 as a partnership among Dr. Michael Rudnicki, one of the country’s foremost stem cell scientists and CEO of the Stemcell Network of Canada, Bloom Burton & Co. – the nation’s largest healthcare investment bank -- and Mr. Frank Gleeson, a serial biotech entrepreneur and former healthcare VC. Satellos has recently completed a seed round of financing to pursue its unique approach of pharmacologically modulating stem cell polarity to stimulate in vivo tissue repair and regeneration. Our initial focus is muscle regeneration, a field in which Dr. Rudnicki is a world leader, with a lead program in Duchenne Muscular Dystrophy.
SATELLOS BIOSCIENCE
Social Links:
Industry:
Pharmaceutical
Founded:
2018-01-01
Address:
Toronto, Ontario, Canada
Country:
Canada
Website Url:
http://www.satellos.com
Total Employee:
1+
Status:
Active
Contact:
905-336-6128
Email Addresses:
[email protected]
Total Funding:
1000 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome Wordpress Plugins
Similar Organizations
Advanced Cell Diagnostics
Advanced Cell Diagnostics is a molecular pathology company developing cell- and tissue-based diagnostic tests for personalized medicine.
Cyagen Biosciences
Cyagen Biosciences is an emerging and innovative biotechnology company.
LivWell Enlightened Health
LivWell Enlightened Health is a medical cannabis company producing and retailing multi-state cannabis.
Current Employees Featured
Founder
Investors List
Parent Project Muscular Dystrophy
Parent Project Muscular Dystrophy investment in Grant - Satellos Bioscience
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-17 | Satellos Bioscience Announces Appointment of J. Robert Hall as Vice-President, Finance and Administration |
Official Site Inspections
http://www.satellos.com Semrush global rank: 5.88 M Semrush visits lastest month: 1.41 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Satellos Bioscience"
About - Satellos
At Satellos, we push boundaries, while staying grounded in biology. Every decision we make is anchored in data and driven by a desire to change what’s possible for people living with …See details»
Satellos Bioscience - Crunchbase Company Profile
Satellos Bioscience is a private regenerative medicine company developing novel therapeutics that stimulate or restore muscle regeneration. The company's …See details»
Satellos Bioscience Inc. - Investor Relations
Satellos is dedicated to developing life-improving medicines to treat degenerative muscle diseases and is building a pipeline of novel therapeutics to promote the body’s innate muscle …See details»
Satellos Bioscience Inc. - Governance - Executive Management
At Satellos, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting …See details»
Satellos Bioscience Closes $55M Financing to Support …
Toronto, Ontario–(May 17, 2023) – Satellos Bioscience Inc. (TSXV: MSCL) (“Satellos” or the “Company“), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases …See details»
Satellos - Overview, News & Similar companies | ZoomInfo.com
Who is Satellos. Satellos was co-founded by biotechnology entrepreneurs Mr. Frank Gleeson and Dr. Michael Rudnicki PhD, FRS, OC to create new therapeutic treatments for degenerative …See details»
Satellos Bioscience Inc. Opens the Market - Newswire
TORONTO, May 15, 2024 /CNW/ - Frank Gleeson Co-Founder and Chief Executive Officer, Satellos Bioscience Inc. (TSX: MSCL) ("Satellos" or the "Company"), and his team joined Dani Lipkin, Managing ...See details»
Satellos to Present at the CureDuchenne FUTURES National …
22 hours ago TORONTO, May 07, 2025--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life …See details»
Satellos Receives Company of the Year Award from Life Sciences …
May 30, 2024 The LSO Awards are an important part of the organization’s goal to advocate for Ontario’s life sciences sector, by celebrating the individuals and companies behind its …See details»
Satellos Announces Management Team Update
Jan 23, 2024 Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSXV: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to …See details»
Satellos to Present at the CureDuchenne FUTURES National …
22 hours ago Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and …See details»
Satellos to Present at the CureDuchenne FUTURES National
10 hours ago TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life …See details»
Satellos Bioscience, Inc. - Drug pipelines, Patents, Clinical ... - Patsnap
About Satellos Bioscience Inc. Satellos is a clinical-stage drug development company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has …See details»
Satellos Bioscience opens the market — OBIO - Ontario Bioscience ...
May 28, 2024 Satellos, a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders, went public on …See details»
Satellos Bioscience Inc. | Newsfile
Satellos to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023. Toronto, Ontario--(Newsfile Corp. - September 20, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) …See details»
Contact - Satellos
Please use the form to direct your message to the appropriate team — Patients, Partnering, Media, or General Information. Please do not submit any personal medical information.See details»
Satellos Recognized as a Top 50 TSX Venture Exchange Company
Feb 21, 2024 Satellos is a publicly traded biotechnology company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has incorporated …See details»
Science - Satellos
Satellos has identified a series of small molecule AAK1 inhibitors and is advancing a lead drug candidate to clinical trials for Duchenne muscular dystrophy. View Duchenne Publications Our …See details»
SATELLOS and iCo Announce Completion of Reverse Takeover
Aug 13, 2021 Toronto, Ontario–(Newsfile Corp. – August 13, 2021) – Satellos Bioscience Inc. (formerly iCo Therapeutics Inc.) (TSXV: MSCL) (“Satellos” or the “Company”) is pleased to …See details»
In the News - Satellos
A selection of press releases and news articles about Satellos. Featured Press Release In the News 05.30.2024. Satellos Receives Company of the Year Award from Life Sciences Ontario …See details»